USMF logo

Institutional Repository in Medical Sciences
of Nicolae Testemitanu State University of Medicine and Pharmacy
of the Republic of Moldova
(IRMS – Nicolae Testemitanu SUMPh)

Biblioteca Stiintifica Medicala
DSpace

University homepage  |  Library homepage

 
Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12710/34466
Title: THERAPEUTIC MANAGEMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE ACCORDING TO THE KDIGO 2025 GUIDELINE
Authors: Celac, Alisa
Guţu, Biatricia
Keywords: ADPKD;tolvaptan;KDIGO guideline;CKD
Issue Date: 2026
Publisher: Centrul Editorial-Poligrafic Medicina
Citation: Celac, Alisa; Guţu, Biatricia. THERAPEUTIC MANAGEMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE ACCORDING TO THE KDIGO 2025 GUIDELINE. In: MedEspera 2026, p. 651. ISBN 978-9975-82-486-6.
Abstract: Introduction. Autosomal dominant polycystic kidney disease (ADPKD) is the most common monogenic kidney disorder, affecting nearly 12 million people worldwide. It is characterized by progressive renal cyst formation leading to kidney enlargement and gradual decline in renal function. ADPKD is a major genetic cause of end-stage kidney disease and often requires kidney replacement therapy. Advances in understanding its pathogenesis have enabled the development of therapies aimed at slowing disease progression. Aim of study. To summarize the main therapeutic approaches recommended by the KDIGO 2025 guideline for the management of autosomal dominant polycystic kidney disease. Methods and materials. A narrative review was conducted based on the KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management and Treatment of ADPKD published in Kidney International. The analysis focused on disease-modifying therapies, management of ADPKD-related complications, and therapeutic strategies for advanced stages of the disease. Results. ADPKD is most frequently caused by mutations in the PKD1 and PKD2 genes encoding polycystin-1 and polycystin-2. Their dysfunction leads to abnormal cellular signaling, progressive cyst growth, and renal parenchymal damage. Therapeutic management includes both standard chronic kidney disease care and disease-specific strategies aimed at slowing progression. Arterial hypertension commonly occurs in early stages; therefore, renin-angiotensin system inhibitors are recommended for blood pressure control and nephroprotection.A major therapeutic advance is tolvaptan, a selective vasopressin V2 receptor antagonist that reduces vasopressin-mediated cyst growth and slows kidney volume increase and decline in glomerular filtration rate in patients with rapidly progressive disease. Treatment requires careful risk -benefit assessment and monitoring of liver function.Management also includes treatment of complications such as cyst infections, nephrolithiasis, and chronic pain, as well as lifestyle measures including sodium restriction and adequate fluid intake. In advanced stages, kidney replacement therapy (dialysis or kidney transplantation) becomes necessary. Conclusions. ADPKD remains a major genetic cause of chronic kidney disease progression. According to the KDIGO 2025 guideline, optimal therapeutic management requires early identification of patients at risk of rapid progression, control of modifiable risk factors, treatment of complications, and the use of disease-modifying therapies such as tolvaptan. Implementation of these strategies may slow disease progression and improve long-term clinical outcomes.
metadata.dc.relation.ispartof: MedEspera 2026. The 11th International Medical Congress for Students and Young Doctors, 6-8 May 2026
URI: https://medespera.md/documents/abstract-book-4.pdf
https://repository.usmf.md/handle/20.500.12710/34466
ISBN: 978-9975-82-486-6
Appears in Collections:MedEspera 2026

Files in This Item:
File Description SizeFormat 
M-651.pdf491.27 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2013  Duraspace - Feedback